Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.

Rood JJM, van Haren MJ, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal. 2019 Sep 10;177:112871. doi: 10.1016/j.jpba.2019.112871. [Epub ahead of print]

PMID:
31539712
2.

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).

van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.

Pharmacol Res. 2019 Aug;146:104297. doi: 10.1016/j.phrs.2019.104297. Epub 2019 Jun 5.

PMID:
31175939
3.

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Li W, Schinkel AH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 1;1122-1123:78-82. doi: 10.1016/j.jchromb.2019.05.026. Epub 2019 May 27.

4.

Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Dogan-Topal B, Li W, Schinkel AH, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:116-123. doi: 10.1016/j.jchromb.2019.02.017. Epub 2019 Feb 16.

5.

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.

Eur J Pharm Biopharm. 2019 Mar;136:120-130. doi: 10.1016/j.ejpb.2019.01.016. Epub 2019 Jan 17.

PMID:
30660696
6.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.

Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.

Int J Pharm. 2019 Feb 10;556:172-180. doi: 10.1016/j.ijpharm.2018.12.014. Epub 2018 Dec 12.

PMID:
30553002
7.

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Wang Y, Schinkel AH, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Dec 1;1102-1103:167-172. doi: 10.1016/j.jchromb.2018.10.023. Epub 2018 Oct 30.

8.

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.

Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.

Pharmacol Res. 2018 Nov;137:47-55. doi: 10.1016/j.phrs.2018.09.020. Epub 2018 Sep 22.

PMID:
30253203
9.

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.

van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.

Mol Pharm. 2018 Nov 5;15(11):5124-5134. doi: 10.1021/acs.molpharmaceut.8b00702. Epub 2018 Oct 10.

PMID:
30247919
10.

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.

Sparidans RW, Li W, Schinkel AH, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Nov 30;161:136-143. doi: 10.1016/j.jpba.2018.08.038. Epub 2018 Aug 19.

PMID:
30149189
11.

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

Rood JJM, Dormans PJA, van Haren MJ, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:14-21. doi: 10.1016/j.jchromb.2018.05.011. Epub 2018 May 11.

12.

P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.

Int J Cancer. 2018 Oct 15;143(8):2029-2038. doi: 10.1002/ijc.31582. Epub 2018 Jul 10.

PMID:
29744867
13.

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

Spatari C, Li W, Schinkel AH, Ragno G, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:204-208. doi: 10.1016/j.jchromb.2018.03.014. Epub 2018 Mar 9.

14.

Quantification of cystine in human renal proximal tubule cells using liquid chromatography-tandem mass spectrometry.

Jamalpoor A, Sparidans RW, Pou Casellas C, Rood JJM, Joshi M, Masereeuw R, Janssen MJ.

Biomed Chromatogr. 2018 Aug;32(8):e4238. doi: 10.1002/bmc.4238. Epub 2018 Apr 15.

15.

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

Gholizadeh S, Dolman EM, Wieriks R, Sparidans RW, Hennink WE, Kok RJ.

Pharm Res. 2018 Mar 7;35(4):85. doi: 10.1007/s11095-018-2373-x.

16.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.

Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH.

Pharmacol Res. 2018 Mar;129:414-423. doi: 10.1016/j.phrs.2017.11.006. Epub 2017 Nov 14.

PMID:
29155017
17.

Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).

Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Pharm. 2017 Oct 2;14(10):3258-3268. doi: 10.1021/acs.molpharmaceut.7b00257. Epub 2017 Sep 19.

PMID:
28880088
18.

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.

Retmana IA, Wang J, Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:300-305. doi: 10.1016/j.jchromb.2017.07.034. Epub 2017 Jul 23.

19.

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.

van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Pharmacol Res. 2017 Jun;120:43-50. doi: 10.1016/j.phrs.2017.01.035. Epub 2017 Mar 10.

PMID:
28288939
20.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.

Sparidans RW, Rosing H, Rood JJM, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:390-398. doi: 10.1016/j.jchromb.2016.09.012. Epub 2016 Sep 11. No abstract available.

PMID:
27639128
21.

PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.

Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T, van Tellingen O.

Clin Cancer Res. 2017 Mar 1;23(5):1286-1298. doi: 10.1158/1078-0432.CCR-16-1276. Epub 2016 Aug 23.

22.

Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.

Rood JJM, van Bussel MTJ, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Sep 15;1031:80-85. doi: 10.1016/j.jchromb.2016.07.037. Epub 2016 Jul 18.

PMID:
27469903
23.

Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology.

Rood JJM, Schellens JHM, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal. 2016 Oct 25;130:244-263. doi: 10.1016/j.jpba.2016.06.037. Epub 2016 Jun 21. Review.

PMID:
27460293
24.

Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma.

Sparidans RW, Kort A, Schinkel AH, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 15;1023-1024:24-9. doi: 10.1016/j.jchromb.2016.04.049. Epub 2016 May 2.

PMID:
27179188
25.

Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.

Sparidans RW, van Hoppe S, Rood JJ, Schinkel AH, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Feb 15;1012-1013:118-23. doi: 10.1016/j.jchromb.2016.01.025. Epub 2016 Jan 21.

PMID:
26826475
26.

Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.

Rood JJM, van Hoppe S, Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal. 2016 Jan 25;118:123-131. doi: 10.1016/j.jpba.2015.10.033. Epub 2015 Oct 27.

PMID:
26540627
27.

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Pharmacol Res. 2015 Dec;102:200-7. doi: 10.1016/j.phrs.2015.09.003. Epub 2015 Sep 8.

PMID:
26361725
28.

The matrikine N-α-PGP couples extracellular matrix fragmentation to endothelial permeability.

Hahn CS, Scott DW, Xu X, Roda MA, Payne GA, Wells JM, Viera L, Winstead CJ, Bratcher P, Sparidans RW, Redegeld FA, Jackson PL, Folkerts G, Blalock JE, Patel RP, Gaggar A.

Sci Adv. 2015;1(3). pii: e1500175.

29.

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.

Dolman ME, Poon E, Ebus ME, den Hartog IJ, van Noesel CJ, Jamin Y, Hallsworth A, Robinson SP, Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron HN, Chesler L, Molenaar JJ.

Clin Cancer Res. 2015 Nov 15;21(22):5100-9. doi: 10.1158/1078-0432.CCR-15-0313. Epub 2015 Jul 22.

30.

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.

Vogel CJ, Smit MA, Maddalo G, Possik PA, Sparidans RW, van der Burg SH, Verdegaal EM, Heck AJ, Samatar AA, Beijnen JH, Altelaar AF, Peeper DS.

Pigment Cell Melanoma Res. 2015 May;28(3):307-17. doi: 10.1111/pcmr.12364. Epub 2015 Apr 6.

PMID:
25728708
31.

Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.

Dolman ME, Westerhout EM, Hamdi M, Schellens JH, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal. 2015 Mar 25;107:403-8. doi: 10.1016/j.jpba.2015.01.026. Epub 2015 Jan 19.

PMID:
25659532
32.

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).

Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Pharm Res. 2015 Jul;32(7):2205-16. doi: 10.1007/s11095-014-1609-7. Epub 2015 Jan 8.

PMID:
25563977
33.

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).

Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH.

Pharm Res. 2015 Jan;32(1):37-46. doi: 10.1007/s11095-014-1442-z. Epub 2014 Jun 25.

PMID:
24962512
34.

P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.

Tang SC, Sparidans RW, Cheung KL, Fukami T, Durmus S, Wagenaar E, Yokoi T, van Vlijmen BJ, Beijnen JH, Schinkel AH.

Clin Cancer Res. 2014 Jun 15;20(12):3133-45. doi: 10.1158/1078-0432.CCR-13-1759. Epub 2014 Apr 11.

35.

Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.

Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW.

Biomed Chromatogr. 2014 Oct;28(10):1366-70. doi: 10.1002/bmc.3176. Epub 2014 Mar 12.

PMID:
24619951
36.

Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.

Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal. 2014 Apr;92:144-8. doi: 10.1016/j.jpba.2014.01.011. Epub 2014 Jan 21.

PMID:
24518133
37.

Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.

Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH.

J Pharm Biomed Anal. 2014 Jan;88:626-9. doi: 10.1016/j.jpba.2013.10.016. Epub 2013 Oct 23.

PMID:
24216281
38.

Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.

Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal. 2014 Jan;88:216-20. doi: 10.1016/j.jpba.2013.08.051. Epub 2013 Sep 12.

PMID:
24080524
39.

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Int J Cancer. 2014 Mar 15;134(6):1484-94. doi: 10.1002/ijc.28475. Epub 2013 Oct 3.

40.

Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma.

Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Sep 1;934:22-5. doi: 10.1016/j.jchromb.2013.06.030. Epub 2013 Jul 4.

PMID:
23892825
41.

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.

Tang SC, de Vries N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

J Pharmacol Exp Ther. 2013 Sep;346(3):486-94. doi: 10.1124/jpet.113.205583. Epub 2013 Jul 10.

PMID:
23843632
42.

P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Pharmacol Res. 2013 Oct;76:9-16. doi: 10.1016/j.phrs.2013.06.009. Epub 2013 Jul 1.

PMID:
23827160
43.

Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.

Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Apr 15;925:124-8. doi: 10.1016/j.jchromb.2013.02.025. Epub 2013 Feb 27.

PMID:
23537694
44.

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease.

Koelink PJ, Overbeek SA, Braber S, Morgan ME, Henricks PA, Abdul Roda M, Verspaget HW, Wolfkamp SC, te Velde AA, Jones CW, Jackson PL, Blalock JE, Sparidans RW, Kruijtzer JA, Garssen J, Folkerts G, Kraneveld AD.

Gut. 2014 Apr;63(4):578-87. doi: 10.1136/gutjnl-2012-303252. Epub 2013 Mar 23.

45.

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Pharm. 2012 Nov 5;9(11):3236-45. doi: 10.1021/mp3003144. Epub 2012 Oct 18.

PMID:
23020847
46.

Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.

Sparidans RW, Tang SC, Nguyen LN, Schinkel AH, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Sep 15;905:150-4. doi: 10.1016/j.jchromb.2012.08.021. Epub 2012 Aug 21.

PMID:
22940474
47.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.

Sparidans RW, Ahmed TT, Muilwijk EW, Welzen ME, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Sep 15;905:137-40. doi: 10.1016/j.jchromb.2012.08.004. Epub 2012 Aug 10.

PMID:
22917595
48.

Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.

Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Pharm. 2012 Sep 4;9(9):2497-504. doi: 10.1021/mp300108c. Epub 2012 Aug 3.

PMID:
22812517
49.

The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS.

Goey AK, Rosing H, Meijerman I, Sparidans RW, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 1;902:151-6. doi: 10.1016/j.jchromb.2012.06.022. Epub 2012 Jun 26.

PMID:
22770780
50.

Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.

Sparidans RW, Durmus S, Xu N, Schinkel AH, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:169-73. doi: 10.1016/j.jchromb.2012.03.020. Epub 2012 Mar 23.

PMID:
22476055

Supplemental Content

Loading ...
Support Center